THE SAFETY AND KINETICS OF INTRAMUSCULAR QUININE IN MALAWIAN CHILDREN WITH MODERATELY SEVERE FALCIPARUM-MALARIA

被引:42
作者
MANSOR, SM
TAYLOR, TE
MCGRATH, CS
EDWARDS, G
WARD, SA
WIRIMA, JJ
MOLYNEUX, ME
机构
[1] UNIV LIVERPOOL,DEPT PHARMACOL & THERAPEUT,LIVERPOOL L69 3BX,ENGLAND
[2] UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,DEPT TROP MED,LIVERPOOL L3 5QA,ENGLAND
[3] UNIV LIVERPOOL,LIVERPOOL SCH TROP MED,DEPT PARASITOL,LIVERPOOL L3 5QA,ENGLAND
[4] KAMAZU CENT HOSP,LILONGWE,MALAWI
[5] MICHIGAN STATE UNIV,DEPT COMMUNITY HLTH SCI,E LANSING,MI 48824
基金
英国惠康基金;
关键词
D O I
10.1016/0035-9203(90)90007-2
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The safety and kinetics of intramuscular quinine(10 mg salt/kg every 8 h for 3 doses)w ere assessedin Malawian children suffering from uncomplicated falciparum malaria, who were unable to take oral antimalarial drugs. Treatment was completed with oral pyrimethamine-sulfadoxine. The mean (+ SD) peak plasma quinine concentration after the first injection was 9*0 (k2.3) ug/ml, at 1.1 (kO.7) h. Mean plasma concentrations increased further after the second and third doses to a maximum of 115 (f2.6) ug/ml at 16.1 (+3*2) h. No hypotension, hypoglycaemia or electrocardiographic abnormalities developed during quinine treatment. These results provide further evidence for the safety of intramuscular quinine in children with moderately severe malaria. Plasma concentrations of cut-acid glycoprotein (AGP) were higher, and the degree of protein binding of quinine was greater, in acute malaria than in convalescence. There was a significant correlation between AGP concentration and the fraction of plasma quinine bound to plasma protein. These findings suggest a role for AGP in the binding of quinine in plasma in vivo and are of interest since unbound quinine is responsible for both the efficacy and toxicity of the drug. © 1990, Royal Society of Tropical Medicine and Hygiene. All rights reserved.
引用
收藏
页码:482 / 487
页数:6
相关论文
共 27 条
[1]   ALKALINE SOLUTIONS FOR PH CONTROL [J].
BATES, RG ;
BOWER, VE .
ANALYTICAL CHEMISTRY, 1956, 28 (08) :1322-1324
[2]  
BERLIN CM, 1975, CLIN PHARMACOL THER, V18, P670
[3]  
CHIGNELL CF, 1977, DRUG FATE METABOLISM, V1, P184
[4]  
Chongsuphajaisiddhi T, 1981, Ann Trop Paediatr, V1, P21
[5]  
CHONGSUPHAJAISIDDHI T, 1979, Southeast Asian Journal of Tropical Medicine and Public Health, V10, P132
[6]   FACTORS AFFECTING QUINIDINE PROTEIN-BINDING IN MAN [J].
EDWARDS, DJ ;
AXELSON, JE ;
SLAUGHTER, RL ;
ELVIN, AT ;
LALKA, D .
CLINICAL PHARMACOKINETICS, 1984, 9 :96-97
[7]   FACTORS AFFECTING QUINIDINE PROTEIN-BINDING IN HUMANS [J].
EDWARDS, DJ ;
AXELSON, JE ;
SLAUGHTER, RL ;
ELVIN, AT ;
LALKA, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (09) :1264-1267
[8]  
FLETCHER W, 1928, STUDIES I MED RES KU, V18
[9]  
HUGHES T. A., 1925, Indian Journal of Medical Research, V13, P321
[10]  
KREMER JMH, 1988, PHARMACOL REV, V40, P1